CD4 and myeloid sarcoma: Nevertheless, despite the intent of aCD20 treatment to remove B cell-mediated immunity, including the effects of B cells in presenting antigen to CD4 T cells, these studies reveal variable levels of residual underlying immune functionality in patients with MS treated with aCD20.